LEADER 04412nam 22010333a 450 001 9910367564003321 005 20250203235427.0 010 $a9783039214648 010 $a3039214640 024 8 $a10.3390/books978-3-03921-464-8 035 $a(CKB)4100000010106106 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/42637 035 $a(ScCtBLL)dde03a7c-32d5-4378-9cf8-13aef749f272 035 $a(OCoLC)1163813930 035 $a(oapen)doab42637 035 $a(EXLCZ)994100000010106106 100 $a20250203i20192019 uu 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCancer Biomarkers and Targets in Digestive Organs$fNelson Yee, Nikki Lee 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 210 1$aBasel, Switzerland :$cMDPI,$d2019. 215 $a1 electronic resource (146 p.) 311 08$a9783039214631 311 08$a3039214632 330 $aIdentification and development of cancer biomarkers and targets have greatly accelerated progress towards precision medicine in oncology. Studies of tumor biology have not only provided insights into the mechanisms underlying carcinogenesis, but also led to discovery of molecules that have been developed into cancer biomarkers and targets. Multi-platforms for molecular characterization of tumors using next-generation genomic sequencing, immunohistochemistry, in situ hybridization, and blood-based biopsies have greatly expanded the portfolio of potential biomarkers and targets. These cancer biomarkers have been developed for diagnosis, early detection, prognosis, and prediction of treatment response. The molecular targets have been exploited for anti-cancer therapy and delivery of therapeutic agents. This Special Issue of Biomedicines focuses on recent advances in the discovery, characterization, translation, and clinical application of cancer biomarkers and targets in malignant diseases of the digestive system. The goal is to stimulate basic and translational research and clinical collaboration in this exciting field with the hope of developing strategies for prevention and early detection/diagnosis of cancer in digestive organs, and improving therapeutic and psychosocial outcomes in patients with these malignant diseases. 606 $aMedicine$2bicssc 610 $aliver graft injury 610 $aHFE 610 $aneurokinin 610 $achemotherapy 610 $aintestinal tumors 610 $atherapeutic targets 610 $abiliary tract carcinoma 610 $ahepatocellular carcinoma 610 $aclinical trial 610 $acell adhesion molecules 610 $acolorectal cancer 610 $abiomarkers 610 $aphenotypic mosaics 610 $agastrointestinal oncology 610 $aAsian Cancer Research Group (ACRG) 610 $abiomarker 610 $apsychosocial support 610 $aprecision therapy 610 $apancreatic carcinoma 610 $aprecision medicine 610 $aLiver transplantation 610 $apredictive biomarkers 610 $aCD274 610 $acholecystokinin 610 $aThe Cancer Genome Atlas (TCGA) 610 $agastrin 610 $apembrolizumab 610 $aimmunotherapy 610 $agastrin-releasing peptide 610 $astereotactic body radiation therapy 610 $aimmunohistochemistry 610 $agastric carcinoma 610 $aliver transplant 610 $aCAM invasion assay 610 $aintragraft gene expression profiles 610 $amolecular profiling 610 $atargeted therapy 610 $aneurotensin 610 $aintestinal disorder 610 $aramucirumab 610 $anext-generation sequencing 610 $acolorectal carcinoma 610 $atumor progenitor 610 $acirculating tumor cells 610 $agastrointestinal malignancies 610 $abombesin 610 $atrastuzumab 610 $asomatostatin 610 $azebrafish 610 $aG protein-coupled receptors 615 7$aMedicine 700 $aYee$b Nelson$01786932 702 $aLee$b Nikki 801 0$bScCtBLL 801 1$bScCtBLL 906 $aBOOK 912 $a9910367564003321 996 $aCancer Biomarkers and Targets in Digestive Organs$94319463 997 $aUNINA